SCHEMBL3531129

SCHEMBL3531129

Cc1ccc(NS(=O)(=O)c2ccccc2)c(Br)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 4/20 0.61
AGTR1 P30556 1/20 0.61
GLO1 Q04760 1/20 0.61
PAX8 Q06710 1/20 0.61
ALDH1A1 P00352 4/20 0.56
KDM4E B2RXH2 1/20 0.56
HPGD P15428 1/20 0.56
HSD17B10 Q99714 1/20 0.56
TSHR P16473 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.51
GAA P10253 1/20 0.51
HTT P42858 1/20 0.51
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
HSD11B1 P28845 1/20 0.48
EDNRB P24530 1/20 0.48
EDNRA P25101 1/20 0.48
METAP2 P50579 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3527563 0.81 CCR4 (0.53) SLC40A1AGTR1GLO1PAX8ALDH1A1
SCHEMBL6984645 0.76 SLC40A1 (1.00) SLC40A1AGTR1GLO1PAX8ALDH1A1
SCHEMBL2766342 0.73 METAP2 (0.64) ALDH1A1GAAHTTMEN1KMT2A
SCHEMBL3531098 0.73 GLO1 (0.56) GLO1ALDH1A1KDM4EGAAMEN1
SCHEMBL21874185 0.73 KEAP1 (0.53) SLC40A1AGTR1ALDH1A1HSD17B10NPSR1
SCHEMBL29967633 0.72 KDM4E (1.00) SLC40A1AGTR1GLO1PAX8ALDH1A1
SCHEMBL6026817 0.72 KDM4E (1.00) SLC40A1AGTR1GLO1PAX8ALDH1A1
SCHEMBL6617964 0.72 SLC40A1 (0.61) SLC40A1AGTR1GLO1PAX8ALDH1A1
SCHEMBL23455718 0.72 METAP2 (0.54) ALDH1A1KDM4ETSHRSMN1; SMN2GAA
SCHEMBL2067538 0.71 ALDH1A1 (0.68) SLC40A1AGTR1GLO1PAX8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728002-B2 Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors LABORATOIRES FOURNIER S.A. (FR) 2010-06-01 US disclosed
US-20090239856-A1 Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors LABORATOIRES FOURNIER S.A. (FR) 2009-09-24 US disclosed
EP-1919474-B1 PYRROLOPYRIDINE DERIVATIVES AND USE OF SAME AS PPAR RECEPTOR MODULATORS FOURNIER LAB SA (FR) 2009-08-05 EP disclosed
US-7557122-B2 Pyrrolopyridine compounds, method of making them and uses thereof LABORATOIRES FOURNIER S.A. (FR) 2009-07-07 US disclosed
US-20080200495-A1 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239856-A1 Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors PPARD, PPARA, PPARG SLC40A1 3063/4885AGTR1 7/4885GLO1 4133/4885
US-20080200495-A1 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof LIPG, PCSK9, PNLIP SLC40A1 1720/4885AGTR1 2239/4885GLO1 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.